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Highlights 40 
 This is a randomised study comparing immediate vs. deferred ART in asymptomatic HIV-41 
positive individuals with CD4 count >500 cells/mm3 for their impact on renal function 42 
 Immediate ART was associated with high eGFR and lower rates of proteinuria over 2 years 43 
of follow-up.  44 
 Whether this benefit translates in to lower risk of chronic kidney disease needs to be 45 
evaluated in future long-term studies. 46 
 47 
ABSTRACT 48 
Background 49 
Both untreated HIV infection and antiretroviral therapy (ART) have been associated with 50 
worsening kidney function. The impact of earlier ART initiation on kidney function has not been 51 
studied. 52 
Methods 53 
The START trial was a randomized comparison of immediate versus deferred ART initiation 54 
among HIV+ persons with CD4+ counts >500 cells/mm3. Serum creatinine and urine dipstick 55 
protein were measured at baseline, months 1, 4, 8, 12, and annually thereafter. We compared 56 
the two arms for changes in estimated glomerular filtration rate (eGFR, using the CKD-EPI 57 
equation) over time using longitudinal mixed models. 58 
Findings 59 
Of 4685 START participants, 4629 (n=2294 in immediate and 2335 in deferred arm) individuals 60 
were included. Median baseline CD4 and eGFR were 651 cells/mm3 and 111·5 mL/min/1·73m2. 61 
ART was initiated in 2271 participants (99%) in the immediate and 1127 participants (48%) in 62 
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the deferred arm, accounting for over 94% and 19% of follow-up time, respectively. Overall, 63 
89% started ART using a tenofovir-based regimen. Over a median follow-up of 2·1 years, the 64 
mean eGFR was 0·56 (95% CI: 0·003-1·11) mL/min/1·73m2 higher in the immediate arm than 65 
the deferred arm. This difference was more prominent after adjustment for current use of 66 
tenofovir or boosted-protease inhibitors (1·85, 95% CI: 1·21-2·50), and was more prominent in 67 
participants of black race (30% overall) (3·90, 95% CI: 2·84-4·97) compared to non-black (1·05, 68 
95% CI: 0·33-1·77) (p<0·001 for interaction). Relative risk for proteinuria in the immediate vs. 69 
deferred arm was 0·74 (95% CI: 0·55-1·00), P=0·049. The incidence of chronic kidney disease as 70 
defined by eGFR < 60 or dipstick proteinuria was low, and there was no significant difference 71 
between treatment arms (incidence rate ratio 0.79, 95% CI 0.59-1.05). 72 
Conclusion 73 
In the short-term, immediate ART initiation was associated with a modestly higher eGFR and 74 
lower risk of proteinuria as opposed to deferring ART- a difference more pronounced in those 75 
with black race. Whether this early benefit translates into a lower risk of chronic kidney disease 76 
requires further follow-up. 77 
Key words: HIV; kidney; CKD; HAART; eGFR; renal function; START; 78 
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INTRODUCTION 81 
Despite dramatic reductions in the incidence of HIV-associated nephropathy (HIVAN- a unique 82 
form of kidney disease that occurs in the setting of advanced HIV disease) with the use of 83 
effective antiretroviral therapy (ART), HIV positive individuals continue to be at higher risk of 84 
chronic kidney disease (CKD) than the general population.(1) In addition to traditional risk 85 
factors such as diabetes and hypertension, HIV-associated immunodeficiency and inflammation 86 
have been shown to adversely affect renal function and increase the risk of CKD.(2, 3)  87 
ART improves overall health and life-expectancy of HIV-positive individuals, and is first-line 88 
therapy for HIVAN.(4) However, prospective observational studies have demonstrated an 89 
association between cumulative exposure to tenofovir disoproxil fumarate (TDF) and boosted 90 
protease inhibitor (bPIs) and decline in estimated glomerular filtration rate (eGFR) and 91 
increased risk of CKD.(5, 6) Among participants in the D:A:D cohort with normal baseline eGFR 92 
followed for a median of over 7 years, TDF use was associated with 14% higher risk of CKD per 93 
year of use after adjusting for key confounders, with the relative risk nearly doubling in 5 94 
years.(6) Prior studies were nonrandomized and were not powered to consider the risk:benefit 95 
of ART or specific ART agents in HIV-positive individuals with high CD4 counts, in whom ART 96 
initiation is now the standard of care. 97 
The START (Strategic Timing of AntiRetroviral Treatment) trial is a randomized controlled 98 
clinical trial of immediate initiation of ART (‘immediate’ arm) versus deferral of ART initiation 99 
until CD4+ counts decline to <350 cells/mm3 or clinical symptoms develop (‘deferred’ arm), 100 
among participants naïve to ART with CD4+ counts >500 cells/mm3.(7) End-stage renal disease 101 
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(ESRD) was a component of the composite endpoint in START.  There were, however, only two 102 
ESRD events, with 1 event occurring in each arm.(7)  103 
In this study we compare the eGFR trajectory over time between the randomized arms of the 104 
START trial. START is an ideal study design to assess the effect of early ART upon kidney 105 
function among persons with relative immune preservation and low risk for AIDS complications.  106 
 107 
METHODS 108 
Study Design and Data Collection 109 
The design and primary findings of the START trial have been described previously,(7) as has the 110 
baseline prevalence of CKD in START participants.(8) Change in eGFR from baseline and the 111 
development of proteinuria were pre-specified secondary endpoints in START. Serum creatinine 112 
and proteinuria by dipstick were measured at baseline, months 1, 4, 8, 12 and annually 113 
thereafter. All laboratory measures were performed on fresh specimens using standardized 114 
assays by clinical laboratories at the local clinical sites. Data in this report include visits up to the 115 
study unblinding on 26 May 2015.  116 
We calculated eGFR using the CKD-EPI(9) equation for the primary analysis, with sensitivity 117 
analyses using the MDRD equation(10) to calculate eGFR. The main outcome was the change in 118 
follow-up eGFR. Data were analysed up to 60 months of follow-up, as few participants had 119 
annual visits beyond that time period. The following secondary outcomes were also analysed: 120 
(i) incidence of reduction in eGFR by ≥30% from baseline, which has been proposed as a 121 
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surrogate marker of CKD progression in clinical trials(11); (ii) incidence of CKD defined as  eGFR 122 
<60 mL/min/1·73m2 or ≥1+ proteinuria; (iii) incidence of a single reading of ≥1+ proteinuria 123 
alone; (iv) incidence of  CKD as a reportable medical condition during the trial, defined by eGFR 124 
< 60 mL/min/1·73m2 and/or abnormal urine sediment over a period of at least three months. 125 
Outcomes (ii) to (iv) were analysed in those without CKD at baseline. 126 
Statistical methods 127 
The overall mean change from baseline in eGFR over follow-up between the immediate and 128 
deferred arms was compared using random effects linear regression (which account for repeat 129 
measurements in an individual) adjusting for follow-up time and baseline eGFR. Follow-up time 130 
was included as a quadratic term to allow for non-linear change in eGFR. We also assessed for 131 
any interaction effect between time and treatment arm. Next, models were further adjusted 132 
for time-updated use of TDF and bPIs. Finally, models were additionally adjusted for baseline 133 
variables including age, sex, race (black vs. other), region of enrolment (categorised as high-134 
income, including Europe/Israel/United States/Australia vs. low-middle income, including Latin 135 
America/Africa/Asia), time since HIV diagnosis, use of injecting drugs, CD4 count, log10 HIV viral 136 
load, proteinuria, body mass index (measured as weight/(height)2 and categorised at 18·5, 25 137 
and 30 kg/m2), hepatitis B or C virus co-infection (defined serologically), diabetes (defined as a 138 
composite based on known diagnosis or receipt of anti-diabetic medications or 8 hour fasting 139 
glucose ≥ 126 mg/dL), hypertension (systolic blood pressure (BP) > 140 mmHg or diastolic BP > 140 
90 mmHg or receipt of anti-hypertensive medication), dyslipidemia (defined as receipt of lipid-141 
lowering drugs or low density lipoprotein ≥ 160 mg/dL), coronary heart disease at baseline, 142 
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current smoking status, and current receipt of angiotensin converting enzyme inhibitors, 143 
angiotensin receptor blocker or non-steroidal anti-inflammatory drugs.  144 
We performed several subgroup analyses for the primary outcome. Before randomization, 145 
clinicians pre-specified the likely ART regimen a participant would initiate as their first regimen. 146 
We assessed if eGFR changes by treatment arm differed by pre-specified regimen, focusing on 147 
the use of TDF or a bPI. Since choices of pre-specified regimens were made before 148 
randomization, these analyses allow a randomized comparison between the treatment arms 149 
among participants designated to initiate the same regimen. Other subgroup analyses included 150 
assessing eGFR treatment group differences by race; and stratifying the eGFR curves by the 151 
baseline 5 year CKD risk (calculated by the D:A:D CKD risk score and categorised as low: <0, 152 
moderate: 0-4 and high: >=5)(12). A sensitivity analysis was performed by censoring the follow-153 
up on starting TDF/bPI; and censoring follow-up at first switch of ART.  154 
Incidence rates of secondary outcomes were calculated, and the overall difference between the 155 
two arms was compared using random effects Poisson regression models.  156 
RESULTS 157 
Of 4685 START study participants, 10 individuals in the immediate arm and 11 individuals in the 158 
deferred arm did not have baseline creatinine values. A further 22 individuals in the immediate 159 
arm and 13 individuals in the deferred arm had no follow-up creatinine data. After exclusions, 160 
the analysis sample included 4629 individuals (2294 in the immediate arm and 2335 in the 161 
deferred arm). Baseline characteristics of the analysis sample were similar to the overall START 162 
study population (data not shown). 163 
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The median (interquartile range, IQR) follow-up time was 2·1 (1·9-3·2) years. Table-1 provides 164 
baseline characteristics by the treatment arm. The median age was 36 (29-44) years, 1241 165 
(26·8%) were women, and 2124 (45·9%) were enrolled from high-income settings. The median 166 
CD4 count was 651 (584-764) cells/mm3, and the median viral load was 4·1 (3·5-4·6) log10 167 
copies/mL. The median eGFR was 111·5 (IQR 98·5-122·5) mL/min/1·73m2 and only 22 (0·4%) 168 
individuals had an eGFR<60 mL/min/1·73m2. A majority of individuals had a low 5-year 169 
predicted risk of CKD based on the D:A:D CKD risk score, and only 267 (5·8%) had a high 5-year 170 
predicted risk of CKD. Overall, baseline characteristics were well balanced between the two 171 
arms (Table-1). 172 
ART was initiated in 2271 participants (99·0%) in the immediate arm and 1127 (48·2%) in the 173 
deferred arm, accounting for over 94% and 19% of follow-up time, respectively. Of those who 174 
started ART, 3017 (89%) included TDF in their initial regimen, and 668 (19·7%) had a bPI in their 175 
first regimen. 176 
Follow-up eGFR by randomised arm 177 
For sake of clarity, all figures show data only up to month 36 (3 years) where majority of the 178 
data were concentrated. Figure-1 provides mean change in eGFR from baseline over time and 179 
Table-2 provides the results from random effects models analysing change in eGFR by 180 
treatment arm. The eGFR tended to decline over time in both arms (figure-1), with an initial dip 181 
at month 1 and then a slower decline over time. On average over follow-up, the eGFR was 0·56 182 
(95% CI: 0·003 to 1·11) mL/min/1·73m2 higher in the immediate than the deferred arm (Table-183 
2). The interaction term between time and treatment arm was not significant, meaning that the 184 
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rate of change over time was similar in both arms (p=0·73). Results were similar when eGFR 185 
was calculated using the MDRD equation with differences of larger magnitude (Figure-1 and 186 
Table-2). After adjustment for the time-updated use of TDF and bPI, the immediate arm had on 187 
average 1·85 (95% CI: 1·21 to 2·50) mL/min/1·73m2 higher eGFR than the deferred arm.  188 
Subgroup and sensitivity analyses of primary outcome 189 
Over follow-up, the difference in eGFR between treatment arms differed by race (black vs. non-190 
black) (P<0·001 for the interaction between treatment arm and race). In participants of black 191 
race, on average the eGFR was 2·43 (95% CI: 1·43-3·42) mL/min/1·73m2 higher in the 192 
immediate than the deferred arm, increasing to 3·90 (95% CI: 2·84-4·97) mL/min/1·73m2 after 193 
adjustment for current use of TDF and bPI. In participants of non-black race, the difference 194 
between treatment arms was less pronounced: the immediate compared to the deferred arm, 195 
had on an average -0·23 (95% CI: -0·87 to 0·42) mL/min/1·73m2 difference in eGFR, or 1·05 196 
(95% CI: 0·33 to 1·77) mL/min/1·73m2 after adjustment for current use of TDF or bPI. 197 
The choice of pre-specified ART regimen (with TDF or PI or both) did not differ significantly by 198 
treatment arm or by the presence of CKD (defined as eGFR<60 or ≥1+ proteinuria) or the mean 199 
eGFR at baseline (data not shown). However, there was a significant interaction between the 200 
pre-specified choice of a TDF-containing regimen and treatment arm for change in eGFR (Figure 201 
2, p = 0·02). The difference in eGFR between treatment arms (immediate – deferred) in those 202 
who were not pre-specified TDF was 2·50 (0·86 to 4·15) mL/min/1·73m2, compared to 0·38 (-203 
0·20 to 0·96) mL/min/1·73m2  in those with pre-specified TDF.  204 
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Supplementary figure-S1 illustrates the change in eGFR over time when follow-up was censored 205 
at the initiation of TDF or bPI in both arms.  In the absence of use of TDF or a bPI, there was an 206 
initial increase in eGFR in the immediate arm and a higher overall eGFR, compared to the 207 
general small decline in eGFR in the deferred arm. Results were similar when follow-up was 208 
censored at the first switch/change in ART regimen (data not shown). Finally, after censoring 209 
the deferred arm at the initiation of ART (i.e. comparing treated vs untreated) and adjusting for 210 
the use of TDF or bPI in the treatment arm, the immediate (i.e. treated) arm had on average 211 
2.24 (95% CI: 1.21 to 2.50) mL/min/1.73m2 higher eGFR than the deferred (i.e. untreated) arm. 212 
Trajectories of change in eGFR and differences by treatment arm appeared to vary by baseline 213 
CKD risk as estimated by the D:A:D CKD risk score (see Supplementary Figure-S2), although with 214 
<6% of individuals at high baseline CKD risk, we did not have enough power to further analyse 215 
this subgroup. In those with low predicted CKD risk (78% of study participants), trends 216 
appeared similar to those in figure 1. In those with moderate or high CKD risk at baseline, eGFR 217 
tended to increase initially (Figure-S2) as opposed to the slight initial decline seen in those with 218 
low CKD risk. While the eGFR appeared to be higher in the immediate arm in those with 219 
moderate to high baseline CKD risk, over time the curves tended to overlap (Figure-S2). 220 
Secondary outcomes 221 
Table-3 provides a comparison of several secondary outcomes. Decline in eGFR by ≥30%, which 222 
has been proposed as a surrogate CKD endpoint, occurred in < 6% of participants with no 223 
significant difference between treatment arms. A composite CKD endpoint of eGFR < 60 or ≥1+ 224 
proteinuria occurred in 422 participants in the immediate arm and 481 participants in the 225 
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deferred arm, but this difference was not statistically significant (IRR 0.79; 95% CI 0.59-1.05, 226 
p=0.10). The development of ≥1+ proteinuria was significantly less common in the immediate 227 
arm compared to the deferred arm (IRR 0.74; 95% CI: 0.55-1.00, P=0.049), although this 228 
difference was only marginally significant. Of the 850 participants who developed ≥1+ 229 
proteinuria, only 161 (19%) had proteinuria of 2+ or higher. Finally, only 10 study-defined CKD 230 
events were reported in trial, 4 and 6 in the immediate and deferred arms, respectively. 231 
 232 
DISCUSSION 233 
In this large international randomised trial, we found that the immediate initiation of ART in 234 
those with CD4 count >500 cells/mm3, as compared to deferring ART until the CD4 count drops 235 
to below 350 cells/mm3 or clinical symptoms appear, was associated with a modestly higher 236 
overall eGFR over a median follow-up of 2·1 years. This difference was especially prominent 237 
when use of known nephrotoxic agents (TDF or a bPI) was accounted for and was more 238 
prominent in participants of black race compared to non-black. Immediate ART was also 239 
associated with a lower risk of incident ≥1+ dipstick proteinuria, with a trend towards lower risk 240 
of several other secondary CKD outcomes.  241 
The START trial found clear benefit of immediate ART at high CD4 cell counts in terms of AIDS, 242 
mortality, and serious non-AIDS clinical events(7). Our study provides further support for 243 
immediate ART and suggests that at least in the short term, immediate ART is also beneficial in 244 
terms of its impact on kidney function (as assessed by eGFR and dipstick proteinria). The 245 
difference in eGFR  between the treatment arms increased after adjusting for TDF or bPI use, 246 
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suggesting that their use may counteract some of the benefits of early ART. Of note, the actual 247 
difference in eGFR between the two arms was quite small, and the clinical impact of such eGFR 248 
differences on the long-term risk of CKD events is unclear. CKD is a slowly progressive disease, 249 
which can take years to manifest. In our study, the median follow-up was only 2.1 years, as the 250 
START trial was stopped by the Data and Safety Monitoring Board (DSMB) because of the 251 
overwhelming benefit to the immediate arm(7). It is therefore possible that early benefit from 252 
immediate ART on eGFR could be attenuated over time with cumulative toxicity from ART. 253 
Convergence of the curves with prolonged follow-up could reflect increasing use of ART in the 254 
deferred arm, attenuation of the benefit in the immediate arm as a result of cumulative 255 
nephrotoxicity, or a combination of both factors. In addition to the risk of progressive CKD, both 256 
lower eGFR and the presence of proteinuria have been associated with higher risk of overall 257 
and cardiovascular mortality.(13) Longer follow-up of this cohort will therefore be critical for 258 
better understanding of the long term impact of additional years spent on ART in the 259 
immediate arm. 260 
The mechanism behind the initial beneficial effect of immediate ART is unclear and is likely to 261 
be multi-factorial. In our study, after censoring the data at the initiation of TDF/bPI, there 262 
appeared to be an initial gain in eGFR in the immediate arm vs. a general slow decline in eGFR 263 
in the deferred arm. ART reduces viral load as well as inflammation and immune activation, all 264 
of which have been associated with loss of eGFR and kidney disease.(14) In one prospective 265 
cohort study, use of ART (compared to no ART) was associated with a slower decline in eGFR 266 
over 3 years of follow-up.(15) Similarly, in another study, ART initiation was associated with an 267 
improvement in proteinuria and albuminuria, although that study did not have an untreated 268 
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control arm.(16) However, in both previous studies, the median baseline CD4 counts were 269 
around 200 to 250 cells/mm3 suggesting significant immunodeficiency before ART initiation. 270 
Our data suggest that even in those with relatively preserved immune function, ART may 271 
provide benefit in terms of kidney function. In our study, results were robust to the adjustment 272 
for time-updated CD4 count and viral load. Whether this short-term benefit from immediate 273 
ART could be explained by changes in inflammatory mediators will need to be examined 274 
carefully in future biomarker studies. Interestingly, the benefit of immediate ART was more 275 
pronounced in individuals of black race. Because genetic susceptibility to HIVAN is strongly 276 
linked to West African ancestry,(17, 18) our findings could suggest a benefit of immediate ART 277 
on subclinical HIVAN or other forms of non-diabetic kidney disease in individuals of black race. 278 
The accuracy of GFR measurement may play a role: we found that the difference between the 279 
two arms was larger in magnitude in MDRD (vs CKD-EPI) eGFR. However, CKD-EPI equation is 280 
thought to be more accurate at GFRs> 60 mL/min/1·73m2 which were the majority in our study. 281 
Finally, we could not fully explain the initial dip in eGFR at month 1 in both arms of our cohort. 282 
The initial decline in eGFR may have been the result of regression to the mean in participants 283 
with higher baseline eGFR, as it was not observed in those with moderate/ high baseline CKD 284 
risk as estimated by the D:A:D risk score. Also, it was not observed in those who were 285 
prescribed a non-TDF regimen (Figure 2b) suggesting that TDF may have had a role at least in 286 
the treatment arm. Future biomarker studies could provide further insight into the mechanism 287 
behind eGFR trajectory over time. 288 
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Our study had several strengths, including a randomized study design with a large number of 289 
participants with a high baseline CD4 count and serial monitoring of creatinine during follow-290 
up. Our sample was also diverse, with participants enrolled from 215 clinical sites in 35 291 
countries, with 30% of self-reported black race and 27% females. The main limitation of our 292 
study was that our participants had a relatively low baseline risk of CKD, based on young age 293 
and low prevalence of traditional CKD risk factors; for example, both diabetes and hepatitis C 294 
virus co-infection were present in < 4% of participants. The follow-up period was also relatively 295 
short due to the early termination of the START trial. Of note, observed benefit in trials that are 296 
terminated early tends to overestimate the true benefit (e.g. benefit could be attenuated over 297 
longer follow-up).(19) Using changes in creatinine-based eGFR, we cannot differentiate 298 
between true changes in glomerular filtration rate and changes based on interference with the 299 
tubular secretion of creatinine. Although the use of cobicistat (n=150 ever used) and 300 
dolutegravir (n=85 ever used) was very rare in START, a similar effect on tubular secretion could 301 
influence the eGFR in the setting of low dose ritonavir, and has even been suggested with 302 
TDF.(20, 21) Changes in eGFR are also insensitive to tubular injury as may occur in individuals 303 
on TDF containing ART and additional markers of tubular injury were not collected in 304 
START.(22-25) START did not collect data on urine protein or albumin to creatinine ratio, which 305 
could help to quantify the degree of proteinuria and distinguish glomerular versus tubular 306 
proteinuria. Finally, newer ART agents such as tenofovir alafenamide, which may mitigate long-307 
term renal toxicity from ART,(26, 27) were not able to be studied as these drugs were not 308 
licensed at the time.   309 
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In summary, our study suggests modest short-term benefit on kidney function from the 310 
immediate initiation of ART in HIV+ individuals with high CD4. This benefit was especially 311 
prominent in individuals of black race and in the absence of TDF or PI/r. Whether the small 312 
observed differences in eGFR will translate into a reduced risk of CKD, and whether the 313 
cumulative effects of nephrotoxic ART agents may counteract these benefits, should be studied 314 
in future long-term studies. 315 
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 432 
Figure-1: Mean change in eGFR from baseline by treatment arm in START trial 433 
Figure-1a: eGFR (mL/min/1.73m2) calculated by CKD-EPI 434 
Figure-1b: eGFR (mL/min/1.73m2) calculated by MDRD 435 
 436 
Figure- 2: Mean change in eGFR (CKD-EPI) from baseline by pre-specified TDF or non-TDF 437 
regimen in START trial 438 
Figure-2a: Pre-specified TDF regimen 439 
Figure-2b: Pre-specified non-TDF regimen 440 
 441 
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Table 1. Baseline characteristics of START study participants by treatment arm 442 
 Immediate  
N (%) or Median [IQR] 
Deferred  
N (%) or Median [IQR] 
Number included 2294 2335 
Demographics   
Age, years   
Age >50 years 
36 [29, 44] 
225 (9.8) 
36 [29, 44] 
238 (10.2) 
Female 610 (26.6)  631 (27.0) 
Race  
Black 
 
691 (30.1) 
 
704 (30.2) 
Region of enrolment 
United States/Europe/Australia (High) 
Latin America/Africa/Asia (Low-Middle) 
 
1054 (45.9)  
1240 (54.1) 
 
1070 (45.8) 
1265 (54.2) 
HIV History   
Likely mode of infection 
     Injecting drug use 
     Sexual contact 
     Other 
 
36 (1.6)  
2143 (93.4) 
115 (5.0)  
 
26 (1.1) 
2181 (93.4) 
128 (5.5) 
Time known to be HIV positive (years) 0.99 [0.35-2.99] 1.08[0.36-3.11] 
Laboratory results   
Baseline CD4, cells/µL 651 [585, 764] 651 [581-764] 
Log10 HIV RNA, copies/mL 4.1 [3.5, 4.6] 4.1 [3.5, 4.6] 
Medical history   
Hepatitis C co-infection  
Missing 
88 (3.9) 
49 (2.1) 
81 (3.6) 
58 (2.5) 
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Hepatitis B co-infection 
Missing 
63 (2.8) 
50 (2.2) 
65 (2.9) 
75 (3.2) 
Clinical measures   
Body mass index, kg/m2 
Median [IQR] 
      <18.5 
     18.5-25 
     25.1-29.9 
     ≥30 
 
22.1 [24.6-28.0] 
68 (3.0) 
1180 (51.4) 
665 (29) 
381 (16.6) 
 
22.1 [24.5-27.7] 
66 (2.8) 
1216 (52.1) 
676 (28.9) 
377 (16.2) 
Systolic blood pressure, mmHg  
Median [IQR] 
       > 140 
 
120 [110, 130] 
220 (9.6) 
 
120.5 [111, 130.5] 
237 (10.1) 
Diastolic blood pressure, mmHg 
Median (IQR) 
       > 90 
 
75.5 [69.5, 82.5] 
185 (8.1) 
 
76.5 [70, 83] 
198 (8.5) 
Diabetes mellitus 74 (3.2) 79 (3.4) 
Hypertension 428 (18.7) 461 (19.7) 
Dyslipidemia 179 (7.8) 200 (8.6) 
Coronary heart disease (CHD) 8 (0.4) 10 (0.4) 
Current smoker 721 (31.4) 755 (32.3) 
Started ART at any time in the follow-up 2271 (99) 1127 (48.2) 
Of those started ART, Initial regimen including 
    Tenofovir disoproxil fumarate 
    Protease inhibitor/ ritonavir 
    Dolutegravir or cobicistat 
 
2012 (88.6) 
419 (18.5) 
2 (0.1) 
 
1005 (89.3) 
249 (22.1) 
67 (5.9) 
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    Rilpivirine 97 (4.3) 140 (12.4) 
Pre-specified ART regimens 
Containing TDF 
Containing PI/r 
Containing both TDF and PI/r 
 
2047 (89) 
381 (16.7) 
339 (14.8) 
 
2067 (88.5) 
424 (18.2) 
366 (15.7) 
Concomitant medications at baseline 
    ACE inhibitor/ angiotensin receptor blocker 
NSAIDS (incl. Aspirin) 
 
127 (5.5) 
118 (5.1) 
 
117 (5.0) 
113 (4.8) 
eGFR-CKD-EPI, mL/min 
Median (IQR) 
     ≥ 90 
     60-89 
     <60 
 
111.7 [98.2, 123] 
1943 (84.7) 
334 (14.6) 
7 (0.3) 
 
111.04 [98.9, 122.4] 
2001 (85.7) 
319 (13.7) 
15 (0.6 
eGFR-MDRD, mL/min 107.6 [92.6, 125.2] 106.8 [93.9, 124.2] 
Dipstick proteinuria ≥1+ 
Unavailable at baseline 
136 (6.0) 
9 (0.4) 
131 (5.7) 
18 (0.8) 
Chronic kidney disease 142 (6.2) 143 (6.2) 
D:A:D CKD risk score 
Low 
Medium 
High 
Unavailable* 
 
1779 (77.6) 
330 (14.4) 
130 (5.7) 
55 (2.4) 
 
1834 (78.5)) 
291 (12.5) 
137 (5.9) 
73 (3.1) 
NOTE: *D:A:D CKD score could not be calculated largely due to either missing hepatitis C variable or 443 
baseline eGFR below 60 mL/min/1.73m2. Chronic kidney disease (CKD) at baseline defined as eGFR 444 
< 60 mL/min and/or dipstick urine protein ≥ 1+ (defined only in those with available information on both 445 
eGFR and dipstick proteinuria). NSAIDS= non-steroidal anti-inflammatory drugs.  446 
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Table-2 Mean difference (immediate minus deferred) in eGFR over follow-up  447 
Outcome Mean difference Immediate arm minus deferred arm (95% CI), P value 
 Adjusted Model 1*  Adjusted Model 2**  Adjusted Model 3***  
eGFR-CKD-EPI 
mL/min/1.73m2 
0.56 (0.003 to 1.11), 0.049 1.85 (1.21 to 2.50) ,   <0.001 1.72  (1.11 to 2.34) ,   
<0.001 
eGFR-MDRD 
mL/min 
1.26 (0.38 to 2.14),    
0.005 
3.43 (2.35 to 4.51),    <0.001 3.21  (2.17 to 4.25),    
<0.001 
*Model 1: adjusted for baseline eGFR and follow-up time  448 
**Model 2: Model 1 additionally adjusted for current receipt of TDF and boosted PI  449 
***Model 3: Model 2  additionally adjusted for age, gender, race, region of enrolment, time since HIV 450 
diagnosis, use of injecting drugs, CD4, viral load, proteinuria, body mass index, hepatitis B/C, diabetes, 451 
hypertension, dyslipidemia, cardiovascular disease, smoking status, use of ACE inhibitors or NSAIDS, all 452 
measured at randomisation. 453 
 454 
 455 
Table-3: Incidence of decline in eGFR by ≥30%, CKD , and Protenuria by treatment arms 456 
Treatment 
Arm 
Decline in eGFR by ≥30% CKD defined as eGFR 
<60 or ≥1+ proteinuria 
≥1+ Proteinuria 
 Events Rate (95%CI) Events Rate (95%CI) Events Rate 
(95%CI) 
Immediate 
ART 
107 1.83 (1.52-
2.22) 
422 8.70 (7.90- 
9.57) 
390 7.96(7.2-
8.79) 
Deferred ART 123 2.11 (1.77-
2.51) 
481 10.05 (9.19- 
11.0) 
460 9.54 (8.70-   
10.45) 
Immediate vs. 
deferred arm 
IRR (95%CI), 
P 
0.85 (0.64-1.13), 0.27 0.79 (0.59-1.05), 0.10 0.74 (0.55-1.00), 0.049 
Note: Rate are per 100 person-years. 457 
 458 
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